Comparative analysis of bi- and trifocal IOL implantation for presbyopia correction
Session Details
Session Title: Presented Poster Session: Multifocal IOLs
Venue: Poster Village: Pod 1
First Author: : K.Pershin RUSSIA
Co Author(s): : N. Pashinova A. Tsygankov O. Miyovich
Abstract Details
Purpose:
Comparative analysis of new diffractive trifocal IOL and known refractive-diffractive and aspheric diffractive bifocal IOLs with asymmetric optics implantation.
Setting:
Excimer Eye Center, Moscow, Russian Federation
Methods:
The study included 122 patients (173 eyes) with presbyopia, who underwent phacoemulsification cataract (n=118) or refractive lenseсtomy (n=55) with implantation of multifocal IOLs AT Lisa tri 839MP (n=24, group I), AcrySof® IQ ReSTOR ® SN6AD1 (n=115, group II) and Lentis Mplus LS-313 MF-30 (n=34, Group III). UCVA and BCVA at various distances were recorded in 7 days, 1 month, 3 months, 6 months, 1 and 3 years after surgery. The follow-up period was 17.6±7.9 months.
Results:
In all the groups there was a statistically significant (p<0.05) increase in UCVA and BCVA at near and far distance in 6 months after surgery compared with preoperative values. BCVA at intermediate distance in I group was 0.97±0.04 (0.9 to 1.0), compared with preoperative values (0.45±0.22, p=0.007). Averages BCVA at intermediate distance in group II (0.76±0.07, 0.6 to 1.0) and III (0.7±0.04, 0.55 to 0.85) were above preoperative values, but not statistically significant (p> 0.1). A statistically significant increase of BCVA at intermediate distance in group I compared to groups II (t=2.51; p=0.04) and III (t=4.14; p=0.025) is shown.
Conclusions:
The frequency of adverse optical effects such as 'halo', 'glare' and blurred vision while driving at night in the group with trifocal IOL implantation is somewhat lower than in the other groups (p>0.1).When comparing BCVA at an intermediate distance between the groups we revealed a statistically significant increase in the group with trifocal IOL implantation (0.97±0.04) compared with groups AcrySof® IQ ReSTOR® SN6AD1 (0.76±0.07) and Lentis Mplus LS-313 MF-30 (0,7 ± 0,04), indicating its benefits for intermediate vision correction.
Financial Disclosure:
NONE
